



Government **B**ioscience **G**rants

UPDATED MONTHLY

August 10, 2021

—  
THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

PUBLISHED BY



## Questions?

Liz Powell, Esq., MPH  
lpowell@G2Gconsulting.com

 [www.G2Gconsulting.com](http://www.G2Gconsulting.com)

 @G2Gconsulting





[www.G2Gconsulting.com/bioscience-corner](http://www.G2Gconsulting.com/bioscience-corner)

## GBG Report Updated Monthly

August 10, 2021

**August 20, 2021 from 10:00am-10:30 am EDT** – Join us for G2G’s Monthly [GBG Report and Highlights Call & Screen Share](#) when we will take a closer look at funding opportunities listed below and close with Q&A. Click [here](#) to register.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
<b>ALZHEIMER’S DISEASE (6)</b>						
1.	Elucidating the Roles of Transposable Elements in AD/ADRD and Aging (R01 Clinical Trial Not Allowed) (NIH/NIA)	RFA-AG-22-021	The goal of this is to support hypothesis-driven research to gain an understanding of the dysregulation of transposable elements (TE) and their contributions to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and aging. This FOA encourages applications that investigate causal effects of TE activation in disease and aging and applications that model therapeutic interventions to facilitate the transition of the field from observational discovery towards a deeper mechanistic understanding of the function and regulation of TEs.	Letter of Intent Due: 10/2/21  Proposal Due: 11/2/21	Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-021.html</a>
2.	Primary Care-Based Screening and Intervention Development for Prevention of Abuse in the Context of Alzheimer’s Disease and Related Dementias (R61/R33 Clinical Trial Required) (NIH/NIA)	RFA-AG-22-024	The purpose of this FOA is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD) and their families. Specifically, this FOA invites R61/R33 applications proposing Stage I screening and behavioral intervention development and Stage III efficacy trials in primary care settings. Studies must directly address the priority research needs and gaps highlighted in the U.S. Preventive Services Task Force’s 2018 final recommendation statement on Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults:	Letter of Intent Due 9/20/21  Proposal Due 10/20/21	Up to \$3 million, for up to 3 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-024.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-024.html</a>

3.	Leveraging Existing Data Resources for Computational Model and Tool Development to Discover Novel Candidate Mechanisms and Biomarkers for AD/DRD (R01 Clinical Trial Not Allowed) (NIH/NIA/NINDS)	RFA-NS-22-006	<p style="text-align: center;"><b>ALZHEIMER'S DISEASE</b></p> <p>The objective of this FOA is to expand the use of existing AD/DRD data resources, via computational model development and dissemination, to drive new discoveries and novel hypotheses that can lead to better understanding of disease mechanisms, clinical risk assessment and outcomes, and to identify novel candidate biomarkers for AD/DRD. The goals of this initiative will be accomplished through the aggregation and harmonization of existing data sets and the integration of those data into broadly shared interactive computational software and models, with the opportunity of using the resulting platform(s) for analyses. These platforms could be at a preclinical level, such as providing a tool for developing novel hypotheses that would otherwise not be apparent without the aggregation of currently disconnected data sets across molecular, cellular, and tissue/organ levels. At a clinical level, these tools could be used to generate disease progression models or clinical trial simulators to inform more efficient clinical trial design by aggregating currently disparate datasets.</p>	<p>Letter of Intent Due: 9/26/21</p> <p>Proposal Due: 10/26/21</p>	<p>Up to \$499,000 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-006.html</a></p>
4.	Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed) (NIH/NINDS/NIA)	RFA-NS-22-001	<p>The purpose of this FOA is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly shareable through the PDBP repositories.</p>	<p>Proposal Due: 10/22/21</p>	<p>Dependent upon proposal; for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-001.html</a></p>
5.	Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in AD/DRD and its Progression (R01 Clinical Trial Not Allowed) (NIH/NINDS/NIA)	PAR-22-023	<p>Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/AD/DRD and have been significantly less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/AD/DRD field and to support further work in this area through investigator-initiated and other mechanisms.</p>	<p>Letter of Intent Due: 9/22/21</p> <p>Proposal Due: 10/22/21</p>	<p>Up to \$500,000 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-023.html">https://grants.nih.gov/grants/guide/pa-files/PAR-22-023.html</a></p>

6.	Pre-Announcement: Alzheimer's Disease Programs Initiative (ADPI) - States and Community Grants (HHS/ACL)	HHS-2022-ACL-AOA-ADPI-0059	<b>ALZHEIMER'S DISEASE</b> Cooperative agreements under the ADPI program are intended to support and promote the development and expansion of dementia-capable home and community-based service (HCBS) systems in States and Communities. There are two application options contained in this single FOA: Grants to States (Option A) and Grants to Communities (Option B). The dementia-capable systems resulting from program activities under either option are expected to provide quality, person-centered services and supports that help individuals living with dementia and their caregiver remain independent and safe in their communities.	Estimated Post Date: 1/25/22 Estimated Due Date: 3/29/22	Up to \$1 million Dependent upon award mechanism	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=335000">https://www.grants.gov/web/grants/view-opportunity.html?oppId=335000</a>
7.	Pre-Announcement: Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer's Disease and Alzheimer's Disease Related Dementias (R01 Clinical Trial Not Allowed) (NIH/NINDS/NIA)	NOT-NS-22-004	The NINDS and the NIA intend to promote a new initiative by publishing a FOA to solicit applications for research on the clinical relevance of the linkage between environmental toxicant exposures and AD/ADRD. There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. The RFA will encourage neuroscientists and environmental health scientists to collaborate and conduct mechanistic AD/ADRD research on the actions of neurotoxicants on the nervous system.	Estimated Post Date: 1/1/22 Estimated Proposal Due Date: 3/1/22	Up to \$750,000	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-22-004.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-22-004.html</a>
<b>ARTIFICIAL INTELLIGENCE (1)</b>						
8.	Pre-announcement: Ensuring Consistency of Systemic Information (EcoSystemic) (DARPA)	DARPA-PA-20-02-12	DARPA is issuing an Artificial Intelligence Exploration (AIE) Opportunity, inviting submissions of innovative basic research concepts in the technical domain of consistency in federated data stores. The Ensuring Consistency of Systemic Information (ECoSystemic) Opportunity aims to develop innovative techniques to improve the mutual consistency of federated backups, together with processes for recovering a distributed system of potentially global scale promptly to a functional and mutually consistent restored state. Robust recovery of information systems has broad applicability in both military and commercial domains.	Proposal Due: 8/31/21	Phase 1: Up to \$667,000 Phase 2: Up to \$333,000	<a href="https://sam.gov/opp/4a697296778a4d96aaca850679f67059/view">https://sam.gov/opp/4a697296778a4d96aaca850679f67059/view</a>

<b>BROAD AGENCY ANNOUNCEMENTS (27)</b>						
9.	BARDA Broad Agency Announcement (HHS/BARDA)	BAA-18-100-SOL-00003	<p>Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. COVID-19 related Areas of Interest includes:</p> <ul style="list-style-type: none"> <li>• Diagnostic Assay for Human Coronaviruses</li> <li>• Diagnostic Assay for Detection of SARS-CoV-2 Virus</li> <li>• Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies</li> <li>• Screening Tests at Point of Care (2-minute Time to Result)</li> </ul>	White Papers Due: 10/31/21	Dependent upon proposal	<a href="https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view">https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view</a>  <a href="https://www.medicalcountermeasures.gov/barda/barda-baa">https://www.medicalcountermeasures.gov/barda/barda-baa</a>
10.	BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA)	BAA-20-100-SOL-0002	<p>BARDA is accepting submissions through the EZ-BAA for the following AOIs, 1) Early Notification to Act, Control and Treat: seeking technologies to identify, characterize, and broadly adapt biological, biometric, behavioral and physiological signatures that can signal health security threat infections or exposures. 2) Infection Severity &amp; Solving Sepsis: catalyzing technologies along the sepsis patient continuum with a focus on technologies that address sepsis. 5) Repurposing Drugs In Response to Chemical Threats: repurpose common therapeutics as medical counter measures and treat the symptoms associated with chemical agent exposure. 6) Beyond the Needle. The goal is to reduce the burden of traditional vaccine delivery via needle and syringe on the healthcare system and supply-chain.</p>	No Due Dates, open until 2/3/23	Up to \$750,000, per award	<a href="https://sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view">https://sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view</a>  <a href="https://drive.hhs.gov/partner.html">https://drive.hhs.gov/partner.html</a>
11.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	<p>This BAA supports extramural R&amp;D ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. R&amp;D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.</p>	<p>No Due Dates, open until 9/30/22</p> <p>Pre-application Required</p> <p>Full Proposal by invitation</p>	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726">https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726</a>  (Full Announcement in Related Documents Tab)

<b>BROAD AGENCY ANNOUNCEMENTS</b>						
12.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF-18-S-0005	Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.	No Due Dates, open until 4/29/23  Full Proposal Required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462">https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462</a>  (Full Announcement in Related Documents Tab)
13.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD)	W911NF-17-S-0002-07	The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	No Due Dates, open until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf</a>
14.	Army Research Office Broad Agency Announcement Staff Research Program (DoD)	W911NF 20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	No Due Dates, open until 2/19/25	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>

15.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD)	W911NF-17-S-0003	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&amp;T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&amp;T Campaigns located at <a href="http://www.arl.army.mil">www.arl.army.mil</a>. These documents are subject to periodic refinements which may result in taxonomy inconsistencies.</p>	No Due Dates, open until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf">https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf</a>
16.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of Interest accepted on a rolling basis though 5/30/22	Dependent upon proposal and award type	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=305999">https://www.grants.gov/web/grants/view-opportunity.html?oppId=305999</a>  (Full Announcement in Related Documents Tab)
17.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996">https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996</a>  (Full Announcement in Related Documents Tab)

<b>BROAD AGENCY ANNOUNCEMENTS</b>						
18.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. Equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Projects may apply existing knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.	Submissions accepted through 7/31/23  Submission of a pre-proposal is required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754">https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754</a>  (Full Announcement in Related Documents Tab)
19.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.	Submissions accepted through 5/1/24  Submission of a pre-proposal is required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517">https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517</a>  (Full Announcement in Related Documents Tab)
20.	United States Military Academy Broad Agency Announcement (DoD)	W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932">https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932</a>  (Full Announcement in Related Documents Tab)



21.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>NVBL is a consortium of National laboratories, taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks.</p>	N/A	Dependent upon solicitation and proposal	<a href="https://science.osti.gov/nvbl">https://science.osti.gov/nvbl</a>
22.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD)	W911QY 20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.	Proposals accepted on a rolling basis until 2/28/25	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285</a>  (Full Announcement in Related Documents Tab)
23.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD)	FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to \$49 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332</a>  (Full Announcement in Related Documents Tab)

<b>BROAD AGENCY ANNOUNCEMENTS</b>						
24.	FY2021 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology (DoD/ONR)	N00014-21-S-B001	The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.	Proposals accepted on a rolling basis until 9/30/21	Dependent upon proposal	<a href="https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements">https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements</a>
25.	Information Innovation Office (I2O) Office-wide (DoD/DARPA)	HR001121S0010	This BAA seeks revolutionary research ideas for topics not being addressed by ongoing I2O programs or other published solicitations. Potential proposers are encouraged to review the current I2O programs and solicitations to avoid proposing efforts that duplicate existing activities or that are responsive to other published I2O solicitations. I2O programs are organized into four thrust areas: Proficient artificial intelligence (AI), Advantage in cyber operations, Confidence in the information domain & Resilient, adaptable, and secure systems.	Abstract Due: 9/23/21  Proposal Due: 10/28/21	Dependent upon proposal	<a href="https://sam.gov/opp/b67c8910977b46f9828101812bb38617/view">https://sam.gov/opp/b67c8910977b46f9828101812bb38617/view</a>
26.	Broad Agency Announcement (BAA) Science & Technology for Advanced Manufacturing Projects (STAMP) (DoD/ONR)	N00014-21-S-B002	The Manufacturing Technology Program (ManTech) is the Defense Department's investment mechanism for staying at the forefront of defense-essential manufacturing capability. The ManTech Program targets the needs of our warfighters and weapon system programs by helping to find and implement affordable low-risk solutions. The focus of this BAA is primarily on projects that continue to advance the systems engineering approach needed for the design, fabrication, and manufacture of structural components to address challenges in system weight, performance, affordability, and/or survivability.	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=329699">https://www.grants.gov/web/grants/view-opportunity.html?oppId=329699</a>  (Full Announcement in Related Documents Tab)
27.	Research Interests of the United States Air Force Academy (DoD)	USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. Research would essentially reveal mechanisms of existing natural systems, methods to incorporate present biological materials in nature, or disclose new capabilities within existing systems and/or materials.	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175">https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175</a>  (Full Announcement in Related Documents Tab)

<b>BROAD AGENCY ANNOUNCEMENTS</b>						
28.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD)	W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. Domains of interest include 1) Personnel Testing & Performance, 2) Learning in Formal and Informal Environments, 3) Organizational Effectiveness and 4) Leader Processes and Measurement.	White Papers Accepted Until: 5/15/22  Proposals Accepted Until: 8/4/22	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391">https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391</a>  (Full Announcement in Related Documents Tab)
29.	Biological Technologies BAA (DoD/DARPA)	HR001121S0025	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the DoD and addresses national security priorities. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biodefense	Abstracts & Proposals accepted on a Rolling Basis until 4/22/22	Dependent upon proposal	<a href="https://sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view">https://sam.gov/opp/df93a5637fc419a8ea392ee949f9c79/view</a>
30.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy)	N66001-21-S-4700	The Naval Information Warfare Center, Pacific (NIWC Pacific) is soliciting white papers and proposals in accordance with Federal Acquisition Regulation (FAR). Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.	White Papers Accepted on a Rolling Basis Until: 6/4/22	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334026">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334026</a>  (Full Announcement in Related Documents Tab)

<b>BROAD AGENCY ANNOUNCEMENTS</b>						
31.	Collaborations for Innovative Research on Aerospace Structure (CIRAS) BAA (DoD/AFRL)	FA86502 1S2205	<p>The Aerospace Vehicles Division (RQV), Aerospace Systems Directorate (RQ), Air Force Research Laboratory (AFRL), is soliciting research in aircraft structural design, analysis, and experimentation, specifically in the following areas:</p> <ol style="list-style-type: none"> <li>1. Innovative structural concepts for reducing weight and/or improving performance</li> <li>2. Generation of realistic load and environmental spectra</li> <li>3. Advanced structural design and analysis methods</li> </ol>	<p>White Paper Accepted on a Rolling Basis</p> <p>Proposal Solicited by Invitation</p>	Dependent upon proposal	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=333471">https://www.grants.gov/web/grants/view-opportunity.html?oppId=333471</a></p> <p>(Full Announcement in Related Documents Tab)</p>
32.	FY21 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy)	N004212 1S0001	<p>The NAWCAD is interested in receiving proposals for research and development projects, which offer potential for advancement and improvement of NAWCAD operations. NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest: Artificial Intelligence/Machine Learning, Data Science &amp; Visualization, Cyber, Quantum, Hypersonic Systems, Test and Evaluation Engineering, Avionics, Sensors &amp; Electronic Warfare, Secure Communications &amp; Networks, Warfare Analysis, Readiness &amp; Sustainment, Materials &amp; Aircraft Structures, Aeromechanics, Mechanical Systems, Power &amp; Propulsion Systems, Human Systems, Support Equipment, &amp; Systems Engineering.</p>	<p>White Papers Accepted on a Rolling Basis Until: 6/2/22</p> <p>Proposal Solicited by Invitation</p>	Dependent upon proposal	<p><a href="https://sam.gov/opp/3a0e0f16bedb42db830347d2c18fc9e9/view">https://sam.gov/opp/3a0e0f16bedb42db830347d2c18fc9e9/view</a></p>
33.	Research Interests of the Air Force Office of Scientific Research (DoD/AFOSR)	FA9550-21-S-0001	<p>The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are managed in within four teams under two scientific Departments: Engineering and Information Science &amp; Physical and Biological Sciences. The Engineering and Complex Systems team within the Engineering and Information Science Branch leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team within the Engineering and Information Science Branch is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research.</p>	<p>White Papers Accepted on a Rolling Basis</p>	Dependent upon proposal, for up to 5 years	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084</a></p> <p>(Full Announcement in Related Documents Tab)</p>

34.	Redefining Possible (DoD/DARPA)	HR00112 1S0029	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The Tactical Technology Office (TTO) of the Defense Advanced Research Projects Agency (DARPA) is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. The mission of the Tactical Technology Office (TTO) is to redefine access and delivery of effects to every domain in the battlespace: space, air, ground, sea, and undersea in support of national security policy. This includes both platforms as well as the enabling support elements for delivering effects, such as unit-level autonomy or human-machine collaboration. TTO accomplishes this mission by placing bold bets on developing new and novel system technologies and conducting platform demonstrations in realistic, operationally relevant conditions to support technology transition.</p>	Proposals Accepted on a Rolling Basis until 6/10/22	Up to \$1 million, for up to 18 months	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334117">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334117</a></p> <p>(Full Announcement in Related Documents Tab)</p>
35.	Defense Sciences Office, Office-wide (DoD/DARPA)	HR00112 1S0032	<p>The mission of the DARPA Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these thrust areas is described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances.</p>	Abstracts Accepted on a Rolling Basis until 6/10/22	Dependent upon proposal	<p><a href="https://sam.gov/opp/f08ce40db929467ab7a8cdac02345b70/view">https://sam.gov/opp/f08ce40db929467ab7a8cdac02345b70/view</a></p> <p>(Full Announcement in Related Documents Tab)</p>

<b>BIOENGINEERING (1)</b>						
36.	Environmental Microbes as a BioEngineering Resource (EMBER) (DoD/DARPA)	HR00112 1S0035	The EMBER program aims to develop novel, bio-based technologies to overcome key challenges facing domestic supply of Rare Earth Elements (REEs) critical to the U.S. and DoD. The EMBER program will leverage the diversity, specificity, and customizability of environmental microbiology to enable new biomining methods for separation, purification, and conversion of REEs into manufacturing-ready forms. Microbes (and/or biomolecules), including those from extreme or metal-rich environments, can be biologically engineered or adapted to bind, assimilate, and manipulate individual REEs. These biological components, once developed, may be assembled into an in-line separation, purification, and recovery workflow resulting in individual, purified REEs. Scalability of EMBER's approach will be demonstrated with proof-of-concept, pilot scale studies aligned with existing mining/waste treatment infrastructure.	Abstract Due: 8/16/21  Proposal Due: 9/27/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=334727">https://www.grants.gov/web/grants/view-opportunity.html?opId=334727</a>  <a href="https://sam.gov/opp/8e7c7d2a79774a8d89e13068c8c6cb54/view">https://sam.gov/opp/8e7c7d2a79774a8d89e13068c8c6cb54/view</a>
<b>BIOMEDICAL RESEARCH (1)</b>						
37.	A Science of Science Policy Approach to Analyzing and Innovating the Biomedical Research Enterprise (SCISIPBIO) (NSF)	NSF 19-547	The National Science Foundation (NSF) and the National Institutes of Health (NIH) are interested in proposals that will propel our understanding of the biomedical research enterprise by drawing from the scientific expertise of the science of science policy research community. NIGMS and SBE are partnering to enable collaboration in research between the SciSIP program and NIGMS. This partnership will result in a portfolio of high quality research to provide scientific analysis of important aspects of the biomedical research enterprise and efforts to foster a diverse, innovative, productive and efficient scientific workforce, from which future scientific leaders will emerge.	Proposal due: 9/9/21 2/9/22 9/9/22	Up to \$250,000 per year, for up to 4 years	<a href="https://www.nsf.gov/pubs/2019/nsf19547/nsf19547.htm">https://www.nsf.gov/pubs/2019/nsf19547/nsf19547.htm</a>
<b>BURN INJURY (1)</b>						
38.	Pre-Announcement: Disability and Rehabilitation Research Projects (DRRP) Program: Burn Injury Model System Centers (HHS/ACL)	HHS-2022-ACL-NIDILRR-DPBU-0037	The Burn Injury Model System Centers provide comprehensive, multidisciplinary services to people with burn injury as a prerequisite for conducting research that contributes to the development of and access to evidence-based burn rehabilitation with the ultimate goal of improving the health and function, community living and participation, and employment outcomes of people with burn injury. Burn Model System Centers generate new knowledge through site-specific research projects, collaborative projects, and contributions of data to the Burn Model System national longitudinal database. Grants will have a 60-month project period with five 12-month budget periods.	Estimated Post Date: 2/8/22	Up to \$470,000, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=334825">https://www.grants.gov/web/grants/view-opportunity.html?opId=334825</a>

CANCER (16)						
39.	NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-286	This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise.	Letter of Intent Due: 10/1/21  Proposal Due: 11/1/21	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-286.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-286.html</a>
40.	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (NIH/NCI)	PAR-21-290	The purpose of this initiative is to support study design and integration of imaging and fluid-based tumor monitoring analyses into one or more therapeutic settings for assessing treatment success, failure or recurrence. The knowledge gained from this initiative is expected to capture dynamic changes and clinically meaningful indices that contribute to conventional clinical and pathologic information. The long-term goal for research supported through this FOA will focus on determination of the precise use of imaging and fluid-based tumor monitoring assay combinations during cancer therapy to accurately monitor treatment response and emergence of resistance.	Letter of Intent Due: 9/5/21 1/5/22 5/5/22  Proposal Due: 10/5/21 2/5/22 6/5/22	Up to \$500,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-290.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-290.html</a>
41.	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-294	The purpose of this FOA is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.	Letter of Intent Due: 9/4/21 1/5/22 5/5/22  Proposal Due: 10/5/21 2/5/22 6/5/22	Up to \$500,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-294.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-294.html</a>

<b>CANCER</b>						
42.	Acquired Resistance to Therapy Network and Data Center (ARTNet; U24/U54 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-052 (U54) RFA-CA-21-053 (U24)	Through this FOA, the NCI invites interested investigators to develop and submit applications to form the Acquired Resistance to Therapy Network (ARTNet). The ARTNet FOA is a new funding opportunity that builds upon the Drug Resistance and Sensitivity Network (DRSN, <a href="#">RFA-CA-17-009</a> ) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence. Central to the ARTNet's structural organization are team science approaches that iteratively bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies.	Letter of Intent Due: 10/1/21 Proposal Due: 11/1/21	Up to \$850,000 per year, for up to 5 years (U54) Up to \$600,000 per year, for up to 5 years (U24)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-052.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-052.html</a> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-053.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-053.html</a>
43.	Pre-Announcement: Pancreatic Cancer Detection Consortium: Rus (U01 Clinical Trial Optional) & MDCU (U24 Clinical Trial Not Allowed) (NIH/NCI)	NOT-CA-21-098 (U01) NOT-CA-21-099 (U24)	The NCI plans to publish a FOA for the establishment of the Research Units (RUs) and a Management and Data Coordination Unit (MDCU). The PCDC will conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC), and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC-RUs will conduct research for the development and testing of new molecular and imaging biomarkers for early detection of PDAC and/or for identifying those patients at high risk of who could be candidates for early intervention. The PCDC-MDCU will serve as the organizational hub for the entire PCDC program. The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, and data management of trans-PCDC collaborative projects, biorepository building, and organizational and logistics support for Consortium-wide calls, meetings and workshops.	Estimated Post Date: 8/20/21 Estimated Proposal Due Date: 11/15/21	U01: Up to \$600,000 per year U24: Up to \$500,000 per year	<a href="https://grants.nih.gov/grants/guide/not-ice-files/NOT-CA-21-098.html">https://grants.nih.gov/grants/guide/not-ice-files/NOT-CA-21-098.html</a> <a href="https://grants.nih.gov/grants/guide/not-ice-files/NOT-CA-21-099.html">https://grants.nih.gov/grants/guide/not-ice-files/NOT-CA-21-099.html</a>
44.	Cancer Prevention-Interception Targeted Agent Discovery Program Centers and Data & Resource Coordination Center (U24/U54 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-038 (U54) RFA-CA-21-039 (U24)	The purpose of RFA-CA-21-038 is to solicit applications for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54). The overall goal of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations. RFA-CA-21-039 solicits Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC).	Letter of Intent Due: 9/7/21 Proposal Due: 10/7/21	Up to \$720,000 per year, for up to 5 years (U54) Up to \$240,000 per year, for up to 5 years (U24)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-038.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-038.html</a> <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-039.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-039.html</a>



<b>CANCER</b>						
45.	Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01/U24 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-041 (U01)  RFA-CA-21-042 (U24)	The purpose of RFA-CA-21-041 is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes. The information obtained through these comprehensive studies should expose new biology-backed vulnerabilities that will inform the development and preclinical testing of novel interventions in PDAC. RFA-CA-21-042 will create a U24 Coordinating and Data Management Center (CDMC) that will support the overall coordination and research aims of the PSRC Research Projects.	Letter of Intent Due: 10/1/21  Proposal Due: 11/1/21	Up to \$600,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-041.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-041.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-042.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-042.html</a>
46.	Canine Cancer Immunotherapy Network and Coordinating Center (K9CIN; U01/U24 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-050 (U01)  RFA-CA-21-051 (U24)	Through RFA-CA-21-050, the NCI will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. RFA-CA-21-051 will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies.	Letter of Intent Due: 8/27/21  Proposal Due: 9/27/21	Up to \$375,000 per year for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-050.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-050.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-051.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-051.html</a>
47.	Research Centers for Cancer Systems Biology and Multi-Consortia Coordinating Center (U24/U54 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-048 (U54)  RFA-CA-21-049 (U24)	The purpose of RFA-CA-21-048 is to solicit multi-project U54 Research Centers to address challenges in basic cancer biology that require a coordinated systems biology approach. These Research Centers will join the existing NCI-supported Cancer Systems Biology Consortium (CSBC). The goals of the CSBC are to (1) advance understanding of mechanisms that underlie fundamental processes in cancer; (2) support the broad application of systems biology approaches in cancer research; and (3) support the growth of a strong, stable, and diverse research community in cancer systems biology. The CSBC will be supported by the Division of Cancer Biology (DCB) Multi-Consortia Coordinating Center (the MC2 Center, solicited under RFA-CA-21-049), a common coordinating body tasked to facilitate collaborations, resource sharing, and outreach activities across multiple basic cancer biology research programs	Letter of Intent Due: 10/12/21 9/19/22  Proposal Due: 11/12/21 10/19/22	Up to \$1.5 million per year, for 5 years (U54)  Up to 1.2 million per year, for 5 years (U24)	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-048.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-048.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-049.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-049.html</a>

48.	2022 NCI SBIR Contract Solicitation	PHS-2022-1	<p style="text-align: center;"><b>CANCER</b></p> <p>The NIH and the CDC are soliciting proposals from small business concerns that possess the R&amp;D expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and SBIR program objectives. 16 of the contract topics involve cancer research. Topics include: Synthetic Biology Gene Circuits for Cancer Therapy, Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes, and Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes. To explore all 16 research topics <a href="#">click here</a>.</p>	Proposal Due: 10/28/21	<p>Phase I: Up to \$400,000 for 1 year</p> <p>Phase II: Up to \$2 million for up to 2 years</p>	<p><a href="https://sbir.cancer.gov/funding/contracts/currentcontracts">https://sbir.cancer.gov/funding/contracts/currentcontracts</a></p> <p><a href="https://sbir.nih.gov/sites/default/files/Contracts-Solicitation-PHS-2022-1.pdf">https://sbir.nih.gov/sites/default/files/Contracts-Solicitation-PHS-2022-1.pdf</a></p>
<b>CENTRAL NERVOUS SYSTEM (3)</b>						
49.	Pre-Announcement: Spinal Cord Injury Model Systems (SCIMS) Multi-Site Collaborative Research Project (HHS/ACL)	HHS-2022-ACL-NIDILRR-SIMS-0025	The Spinal Cord Injury Model System (SCIMS) Centers provide comprehensive, multidisciplinary services to people with spinal cord injury as a prerequisite for conducting research that contributes to the development of and access to evidence-based rehabilitation with the ultimate goal of improving the health and function, community living and participation, and employment outcomes of people with spinal cord injury. The purpose of this SCIMS multi-site collaborative research project is to utilize the collaborative capacity of the SCIMS Centers to conduct high quality multi-site research toward improving outcomes of people with SCI.	Estimated Post Date: 2/15/22	Up to \$900,000, for 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334845">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334845</a>
50.	BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 Clinical Trial Required/Not Allowed) (NIH)	RFA-NS-19-002 RFA-NS-19-003 NOT-NS-21-062 (U19 Clinical Trial Required)	<p>These RFAs support integrated, interdisciplinary research teams from prior BRAIN technology and/or integrated approaches teams, and/or new projects from the research community that focus on examining circuit functions related to behavior, using advanced and innovative technologies. Projects will incorporate overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Programs should employ multi-component teams of research expertise – including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration.</p> <p>These RFAs are forecasted to be renewed and reposted on 11/1/21, with an estimated proposal due date of 10/1/22.</p>	Letter of Intent Due: 9/29/21  Proposal Due: 10/29/21	Dependent upon proposal, for 5 years	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-002.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-002.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-003.html</a></p>

<b>CLINICAL TRIALS (1)</b>						
51.	Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required) (NIH)	RFA-HL-22-014	The NIH participating Institutes and Centers, in coordination with the FDA, seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This FOA, issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials.	Proposal Due: 10/8/21	Up to \$350,000 per year, for up to 5 years  Matching funds required	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-014.html</a>
<b>COGNITIVE NEUROSCIENCE (1)</b>						
52.	Cognitive Neuroscience (NSF)	PD-15-1699	The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by the program include attention, learning, memory, decision-making, language, social cognition, and emotions. Proposals with animal models are appropriate only if they include a comparative element with human subjects.	Proposal Due: 8/13/21 2/11/22 8/13/22	Average award is \$175,000 per year, for 3 years	<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5316">https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5316</a>
<b>COMBAT READINESS (1)</b>						
53.	FY21 Combat Readiness – Medical Research Program (DoD/CDMRP)	W81XWH-21-S-CRRP	The FY21 CRRP will solicit research applications addressing at least one of the Focus Areas described below through one award: the Rapid Development and Translational Research Award. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury. Focus areas are: 1) Solutions to enhance Warfighter readiness, 2) Solutions to enhance combat care delivery throughout the far-forward environment, & 3) Wound-care solutions for complex trauma and tissue regeneration.	Pre-Application Due: 8/31/21  Full Application by Invitation	Up to \$1.8 million, for up to 2 years	<a href="https://cdmrp.army.mil/funding/crrp">https://cdmrp.army.mil/funding/crrp</a>

<b>COMPUTATIONAL GENOMICS (2)</b>						
54.	Investigator Initiated Research in Computational Genomics and Data Science (R01/R21 Clinical Trial Not Allowed) (NIH/NHGRI)	PAR-21-254 (R01) PAR-21-255 (R21)	These FOAs invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. These FOAs support fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.	Proposal Due: 10/5/21 2/5/22 6/5/22 (R01)  Proposal Due: 10/16/21 2/16/22 6/16/22 (R21)	Up to \$500,000, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-254.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-254.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-255.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-255.html</a>
<b>CORONAVIRUS (3)</b>						
55.	Limited Competition Emergency Awards: Shared PPE Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (NIH)	PAR-21-276	The purpose of this public health emergency funding opportunity is to provide PPE to directly support the needs of the NIAID's vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID's emergency appropriation provided by "The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020," "The Coronavirus Aid, Relief and Economic Security (CARES) Act", "The Coronavirus Response and Relief Supplemental Appropriations Act, 2021" and "The American Rescue Plan Act of 2021."	Proposals accepted on a rolling basis through 7/16/22	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-276.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-276.html</a>

56.	Pre-Announcement: Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19 (CDC/ERA)	RFA-IP-22-003	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The purpose of this NOFO is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.</p> <p>Eligibility limited to nonprofit organizations, institutions of higher learning, and government entities</p>	<p>Estimated Post Date: 9/1/21</p> <p>Estimated Proposal Due Date: 11/1/21</p>	Up to \$4 million	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334855">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334855</a>
57.	Pre-Announcement: AHRQ COVID 19 NOFO (HHS/AHRQ)	PA-22-054	<p>This NOFO will support new investigator-initiated research (IIR) grants focused on COVID-19.</p> <p>Eligibility limited to nonprofit organizations, institutions of higher learning, and government entities</p>	Estimated Post Date: 3/19/22	TBD	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=335210">https://www.grants.gov/web/grants/view-opportunity.html?oppId=335210</a>
<b>DIABETES (4)</b>						
58.	Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes, Clinical Centers and Biostatistics Research Center (U01 Clinical Trial Not Allowed) (NIH/NIDDK)	RFA-DK-21-002 (Clinical Centers) RFA-DK-21-003 (BRC)	These FOAs create a clinical consortium and a BRC to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.	<p>Letter of Intent Due: 2/3/22</p> <p>Proposal Due: 3/3/22</p>	<p>Up to \$500,000 per year, for up to 5 years (Clinical Centers)</p> <p>Up to \$2.5 million per year, for up to 5 years (BRC)</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-002.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-002.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-003.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-003.html</a></p>

59.	Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus (R01 Clinical Trial Required) (NIH/NIDDK)	RFA-DK-21-018	<p style="text-align: center;"><b>DIABETES</b></p> <p>The overarching goal of this FOA is to reduce racial and ethnic health disparities in T1D through improving diabetes technology usage in individuals with T1D from racial and ethnic underrepresented backgrounds. As such, this FOA invites investigator-initiated applications which propose pilot and feasibility clinical trials to refine interventions with stakeholder guidance and test subsequent interventions to overcome barriers and improve access, initiation, and/or sustained use of diabetes technology in this population. Successful trials will provide feasibility information as well as pilot data on health outcomes and patient reported outcomes associated with improved technology adoption. Proposed interventions are encouraged across the lifespan but should be developmentally appropriate for the target population.</p>	<p>Letter of Intent Due: 2/3/22</p> <p>Proposal Due: 3/3/22</p>	<p>Up to \$200,000 for grant year 1</p> <p>Up to \$300,000 per year, for grant years 2-4</p>	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-018.html</a>
60.	Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed) (NIH/NIDDK/NHLBI)	RFA-DK-21-010	<p>This FOA invites a single cooperative agreement application for a data coordinating center that first establishes a biorepository of human cardiovascular (CV) tissue and then serves as a coordinating center resource for discovery and mechanistic research to increase our knowledge of the CV complications of type 1 diabetes (T1D). Cardiovascular disease (CVD) is the leading cause of death and morbidity for individuals with T1D, but no T1D-specific therapy exists to prevent or treat this complication of diabetes because of challenges from inadequate preclinical models, decades-long disease progression and poorly defined differences in pathogenesis compared to type 2 diabetes (T2D).</p>	<p>Letter of Intent Due: 9/20/21</p> <p>Proposal Due: 10/20/21</p>	<p>Up to \$1 million per year, for years 1-2</p> <p>Up to \$1.3 million per year, for years 3-5</p>	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-010.html</a>
<b>FUNGAL DISEASES (1)</b>						
61.	Pre-Announcement: Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases (CDC/ERA)	RFA-CK-22-006	<p>The purpose of this notice of funding opportunity is to support clinical and applied research that will ultimately help reduce illness and death due to fungal diseases around the world caused by both known and emerging pathogens.</p>	<p>Estimated Post Date: 1/4/22</p> <p>Estimated Proposal Due Date: 3/4/22</p>	<p>Up to \$250,000</p>	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334842">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334842</a>

<b>HEALTHCARE DISPARITIES (3)</b>						
62.	Network of the National Library of Medicine All of Us Program Center (U24) (Clinical Trial Optional) (NIH)	RFA-LM-21-002	This FOA invites cooperative agreement (U24) applications for the Network of the National Library of Medicine (NNLM) All of Us Program Center (NAPC). The mission of the NNLM is to provide U.S. health professionals, researchers, public health workforce, educators, and the public with equal access to biomedical and health information resources and data. NNLM's main goals are to work through libraries and other members to support a highly-trained workforce for biomedical and health information resources and data, improve health literacy, and increase health equity through information.	Letter of Intent Due: 8/17/21  Proposal Due: 9/17/21	Up to \$3.2 million per year, for up to 4 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-LM-21-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-LM-21-002.html</a>
63.	Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional) (NIH)	PAR-21-287	The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs improve the health of at-risk populations such as sexual and gender minority youth, immigrant youth, and youth who reside in rural areas are also a relevant focus for understanding effective models of SBHCs. Applications are expected to provide a conceptual model that describes hypothesized causal pathways by which SBHCs engage underserved youth to improve health outcomes and how SBHCs may complement (or reduce) the use of other services.	Proposal Due: 2/5/22 6/5/22 10/5/22	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-287.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-21-287.html#_Section II. Award 1</a>
64.	Pre-Announcement: OEREP- Scalable Interventions That Significantly Reduce High Burden Racial and Ethnic Disparities (R18) (HHS/AHRQ)	RFA-HS-22-001	The purpose of this NOFO is to support existing evidence for reducing or eliminating healthcare disparities and implement interventions; and to apply interventions in expanded settings (from original evidence) to uncover evidence in different contexts.  Eligibility limited to nonprofit organizations, institutions of higher learning, and government entities	Estimated Post Date: 5/17/22  Estimated Proposal Due Date: 7/18/22	TBD	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=335206">https://www.grants.gov/web/grants/view-opportunity.html?oppId=335206</a>

IMMUNOLOGY & INFECTIOUS DISEASES (4)						
65.	Notice of Special Interest: Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research (NIH)	NOT-AI-21-071 PA-20-185 PA-20-195	<p>The purpose of this NOSI is to evaluate the utility of CC and CC-RIX mouse lines for research areas of interest to NIAID. These research areas include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Studies of immune system development, regulation, and function during homeostasis or in response to infections, vaccinations, or alloantigens across the lifespan.</li> <li>• Development and characterization of new models for autoimmune diseases, asthma and allergic diseases, allograft rejection and/or tolerance designed to better-predict the human clinical experience.</li> <li>• Characterization of biomarkers for prediction of allograft rejection and/or tolerance, and identification of novel targets for immunosuppressive or immune-altering drugs with the goal of effectively preventing allograft rejection and/or promoting tolerance without compromising protective immunity, or otherwise improving-upon current non-specific immunosuppressive therapies used in transplantation.</li> <li>• Studies of infectious disease pathogenesis with the goal of identifying: Novel targets/antigens for vaccine development and therapeutics development, Novel animal models for infectious disease research, Infectious disease-related biomarkers for predicting susceptibility to infection or infectious diseases and response to therapeutics or vaccinations.</li> </ul>	Proposal Due: 10/5/21 10/16/21	Up to \$275,000  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-071.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-071.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-195.html">https://grants.nih.gov/grants/guide/pa-files/pa-20-195.html</a>
66.	Notice of Special Interest: Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes (NIH/NIAID/ NHLBI)	NOT-AI-21-067 PA-20-185 PA-20-195	<p>The NIAID is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogeneic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use. This NOSI aims to stimulate multidisciplinary research collaborations that utilize cutting-edge technologies to apply progress made in SCGE to transplantation research. Research funded by this NOSI may utilize various models, including human tissues or organs excluded from clinical use and/or rodent, porcine, or nonhuman primate models. The research should address unmet needs in VCA, islet, or organ allotransplantation, such as the prevention or treatment of rejection; achievement of transplant tolerance; prolongation of allograft survival; protection from the toxicities of pharmacologic immunosuppression; and improvements in the organ/cellular function of transplanted grafts.</p>	Proposal Due: 10/5/21 10/16/21	Up to \$275,000  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-067.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-067.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-195.html">https://grants.nih.gov/grants/guide/pa-files/pa-20-195.html</a>



<b>MENTAL HEALTH (2)</b>						
67.	Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01/R21 Clinical Trial Optional) (NIH/NIMH)	PAR-21-288 (R21)  PAR-21-289 (R01)	The purpose of this FOA is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged.	Proposal Due: 10/5/21 2/5/22 6/2/22 (R01)  Proposal Due: 10/16/21 2/16/22 6/16/22 (R21)	Dependent upon proposal, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-288.html">https://grants.nih.gov/grants/guide/pa-files/PA-21-288.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-289.html">https://grants.nih.gov/grants/guide/pa-files/PA-21-289.html</a>
<b>MICROBIOME RESEARCH (2)</b>						
68	Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders (NIH/NINDS/NICHD/NIDDK)	NOT-NS-22-003  NOT-DK-21-024  PA-20-185  PA-20-195	These Notices were published to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders. Areas of programmatic interest include, but are not limited to: Identifying the etiology of these conditions, including mechanisms involving central, peripheral, and enteric nervous systems; brain/gut interactions; immunological or neuroimmunological factors; or other genetic or environmental susceptibility factors; Understanding disease as they are influenced by the underlying neurodevelopmental disorder; Developing model systems to study pathogenesis and serve as screening platforms for more reliable diagnosis, prevention, or therapy development; Accurately diagnosing these conditions, including imaging- or electrophysiology-based techniques; Developing biomarkers for use in clinical studies/trials for these conditions or developing pharmacodynamic biomarkers for use in preclinical therapy development for the same conditions; Developing and validating clinical outcome assessment measures for use in clinical trials; Developing treatments, including potential novel therapies or drug/biologic repurposing.	Proposal Due: 10/5/21 or 10/16/21 dependent upon award	Up to \$275,000  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/not-ice-files/NOT-NS-22-003.html">https://grants.nih.gov/grants/guide/not-ice-files/NOT-NS-22-003.html</a>  <a href="https://grants.nih.gov/grants/guide/not-ice-files/NOT-DK-21-024.html">https://grants.nih.gov/grants/guide/not-ice-files/NOT-DK-21-024.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html</a>

			<b>NEUROSCIENCE, NEUROLOGICAL DISEASE &amp; INJURY (10)</b>			
69.	NINDS Exploratory Clinical Trials for Small Business (R41/R42 or R43/44 Clinical Trial Required) (NIH/NINDS)	PAR-21- 266 (R43/44)  PAR-21- 267 (R41/42)	These FOAs provide a vehicle for SBCs submitting SBIR grant applications for investigator-initiated exploratory clinical trials to the NINDS. The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. The goal of these FOAs is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. To achieve this goal, the FOA aims to facilitate the transition of clinical-stage projects to the commercialization stage by encouraging business relationships between NIH's SBIR/STTR awardees and third-party investors and/or strategic partners.	Letter of Intent Due: 8/5/21 12/5/21 3/5/22  Proposal Due: 9/5/21 1/5/22 4/5/22	Phase I: Up to \$1 million, for up to 2 years  Phase II: Up to \$4.5 million, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-266.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-266.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-267.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-267.html</a>
70.	Imaging - Science Track Award for Research Transition (I/START) (R03) (NIH/NIDA)	PAR-21- 309  PAR-21- 310	These FOAs encourage Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies.	Proposal Due: 10/16/21 2/16/22 6/16/22	Up to \$150,000, for 1 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-309.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-309.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-310.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-310.html</a>
71.	BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) (NIH)	RFA- MH-21- 205	Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this FOA from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this FOA are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.	Letter of Intent Due: 9/13/21 9/10/22 9/10/23  Proposal Due: 10/13/21 10/10/22 10/10/23	Up to \$300,000 per year, for 4 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-205.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-205.html</a>

72.	BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases, Specialized Cell Atlases & Coordinating Unit (CUBIE) (NIH)	RFA-MH-21-235 (UM1) RFA-MH-21-236 (U01) RFA-MH-21-237 (U24)	<p><b>NEUROSCIENCE, NEUROLOGICAL DISEASE &amp; INJURY</b></p> <p>The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders. RFA MH 21-235 supports a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. RFA-MH 21-236 supports a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to complement the Comprehensive Centers with distinct capabilities, competencies, and research aims in creating brain cell atlases. RFA MH 21-237 supports an integrated Coordinating Unit of Biostatistics, Informatics, and Engagement (CUBIE) that will coordinate the research activities within and beyond the BICAN.</p>	Letter of Intent Due: 10/9/21 Proposal Due: 11/9/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-235.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-235.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-236.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-236.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-237.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-237.html</a>
73.	Pre-Announcement: BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Clinical Trial Required) (NIH)	NOT-NS-21-064	Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures.	Estimated Post Date: 11/1/21 Estimated Proposal Due Date: 10/1/22	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-064.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-21-064.html</a>

74.	Pre-Announcement: Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention -- Cycle 3 2021 (PCORI)	N/A	<p><b>NEUROSCIENCE, NEUROLOGICAL DISEASE &amp; INJURY</b></p> <p>PCORI intends to release a Funding Announcement (PFA), seeking to fund rigorous, large-scale pragmatic trials that compare newly available pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine. PCORI's Targeted PFA will solicit applications that respond to the following question: What is the comparative effectiveness of novel pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine? PCORI is particularly interested in studies that compare emerging pharmacological options such as CGRP antagonists to standard prophylactic therapy or to each other. PCORI is also interested in studies that examine the comparative effectiveness of evidence-based nonpharmacological options for migraine prevention. As appropriate, studies may include nonpharmacological interventions as stand-alone therapy or as an adjunct to pharmacological options.</p>	<p>Post Date: 9/7/21</p> <p>Letter of Intent Due: 10/5/21</p> <p>Proposal by Invitation, Due: 1/11/22</p>	<p>Up to \$40 million, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://www.pcori.org/funding-opportunities/announcement/pharmacologic-nonpharmacologic-treatments-migraine-prevention-cycle-3-2021">https://www.pcori.org/funding-opportunities/announcement/pharmacologic-nonpharmacologic-treatments-migraine-prevention-cycle-3-2021</a></p>
<b>OMICS (3)</b>						
75.	Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UMI Clinical Trial Not Allowed); Data Analysis and Validation Centers (U01 Clinical Trial Not Allowed); Data Resource and Administrative Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NHGRI)	<p>RFA-HG-21-029</p> <p>RFA-HG-21-030</p> <p>RFA-HG-21-031</p>	<p>The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase 1 will also assess the scale limitations of such methods, develop common data formats, establish "use cases" for this catalog, and inform whether and how a potential second phase will be implemented. RFA-HG-21-029 seeks applications for MorPhiC Data Production Research and Development Centers, which will develop diverse systems and assays and explore and compare approaches to produce MorPhiC data at scale, and to maximize its informativeness. RFA-HG-21-030 seeks applications for MorPhiC Data Analysis and Validation Centers. These Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. RFA-HG-21-031 seeks applications for a Data Resource and Administrative Coordination Center that will be responsible for handling consortium-generated data and disseminating this information to the wider biomedical research community, as well as providing administrative coordination.</p>	<p>UM1 &amp; U24 Letter of Intent Due: 9/15/21</p> <p>U01 Letter of Intent Due: 10/1/21</p> <p>Proposal Due: 11/1/21</p>	<p>UM1: Up to \$1.1 million per year, for up to 5 years</p> <p>U01: Up to \$300,000 per year, for up to 5 years</p> <p>U24: Dependent upon proposal, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-029.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-029.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-030.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-030.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-031.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-031.html</a></p>

			<b>OSTEOPOROSIS (1)</b>			
76.	Pre-Announcement: Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures – Cycle 3 2021 (PCORI)	N/A	Fracture is a significant consequence from osteoporosis with estimates of one in two women and up to one in four men experiencing a fracture in their lifetime due to osteoporosis, which translates to about 2 million people affected annually. Consequences of osteoporotic-related fractures include significant mortality and morbidity, with decreases in functional independence, quality of life, and ability to live in the community. Another consequence of fracture is a subsequent fracture, with about 10 percent refracturing within 1 year and 30 percent within 5 years. Osteoporosis treatment is multimodal and includes drug therapies and nonpharmacological interventions. While evidence exists for single interventions, broad evidence gaps exist around multimodal interventions to prevent second fractures and stakeholders have identified more research as a priority. This Targeted PCORI Funding Announcement will solicit applications that respond to the following question: What is the comparative effectiveness of multimodal treatment interventions (i.e., combination of pharmacologic and/or non-pharmacologic) on patient-centered outcomes in people with osteoporosis and a history of fractures?	Post Date: 9/7/21  Letter of Intent Due: 10/5/21  Proposal Due: 1/11/22	Up to \$40 million, for up to 4 years	<a href="https://www.pcori.org/funding-opportunities/announcement/multimodal-interventions-prevent-osteoporotic-fractures-cycle-3-2021">https://www.pcori.org/funding-opportunities/announcement/multimodal-interventions-prevent-osteoporotic-fractures-cycle-3-2021</a>
			<b>PAIN MANAGEMENT (1)</b>			
77.	Pre-Announcement: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (NIH)	NOT-AT-21-012	The NIH intends to publish one FOA to solicit applications on the development of innovative quantitative imaging and other relevant biomarkers of myofascial tissues for pain management in human subjects using a two-phase grant funding mechanism. Candidates for such biomarkers may include objective measures based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiological approaches, or their integration with other markers through multiscale modeling or machine learning analysis.	Estimated Post Date: 9/15/22  Estimated Due Date: 12/15/21	Funding levels TBD  Phase I: Funded for up to 2 years  Phase II: Funded for up to 3 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-012.html</a>

PATIENT-CENTERED RESEARCH (5)						
78.	Pre-Announcement: Engagement Award: Capacity Building -- October 2021 Cycle (PCORI)	N/A	This funding announcement offers an opportunity for organizations and community groups to build capacity and skills for patient-centered outcomes research and comparative clinical effectiveness research (PCOR/CER). PCORI is receptive to applications to the Engagement Award: Capacity Building encompassing a wide range of research support project topics. This opportunity aims to support projects that help communities increase their facility with and ability to participate across all phases of the PCOR/CER process. Within this announcement, we express two special areas of interest: (1) intellectual and developmental disabilities and (2) maternal morbidity and mortality.	Post Date: 9/7/21  Letter of Intent Due: 10/1/21  Proposal by Invitation, Due: 1/10/22	Up to \$250,000, for up to 2 years	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2021-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2021-cycle</a>
79.	Pre-Announcement: Engagement Award: Dissemination Initiative -- October 2021 Cycle (PCORI)	N/A	The dissemination of research findings to targeted end users is an important part of promoting the uptake of these findings into policy and practice. In many cases, the role of a “trusted source” in raising awareness of new evidence or placing it in an appropriate context is critical to enabling the uptake of this evidence into practice. This Engagement Award initiative focuses on supporting organizations that are trusted sources for their patient, professional, or other community, to undertake dissemination activities. Applicants for an Engagement Award: Dissemination Initiative will be required to focus their project on one of two tracks—Building Capacity for Dissemination or Active Dissemination—and will self-select the focus at the time of LOI submission.	Post Date: 9/7/21  Letter of Intent Due: 10/1/21  Proposal by Invitation, 1/10/22	Up to \$250,000, for up to 2 years	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-dissemination-initiative-october-2021-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-dissemination-initiative-october-2021-cycle</a>
80.	Pre-Announcement: Engagement Award: Stakeholder Convening Support -- October 2021 Cycle (PCORI)	N/A	Through this award, PCORI seeks to fund projects designed by organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. These convenings must have a focus on, and commitment to, supporting collaboration around PCOR/CER. Convenings supported under this funding opportunity should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. Within this announcement, we express three special areas of interest: (1) consideration of the full range of outcomes data, (2) intellectual and developmental disabilities, and (3) maternal morbidity and mortality.	Post Date: 9/7/21  Letter of Intent Due: 10/1/21  Proposal by Invitation, Due: 1/10/22	Up to \$100,000, for up to 1 year	<a href="https://www.pcori.org/funding-opportunities/announcement/engagement-stakeholder-convening-support-october-2021-cycle">https://www.pcori.org/funding-opportunities/announcement/engagement-stakeholder-convening-support-october-2021-cycle</a>

81.	Pre-Announcement: Broad PCORI Funding Announcements - Cycle 3 2021 (PCORI)	N/A	<p style="text-align: center;"><b>PATIENT-CENTERED RESEARCH</b></p> <p>The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. In addition to these four priority areas, PCORI's 2019 reauthorizing legislation provided additional direction about national research priorities to include research with respect to intellectual and developmental disabilities and to maternal mortality. Beginning Cycle 3 2021, PCORI has identified two Special Area of Emphasis (SAEs) to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged and patient-centered comparative clinical effectiveness research. These SAEs are Telehealth for Chronic Disease Management among Vulnerable Populations with Complex Needs and Addressing Racism, Discrimination, and Bias in Healthcare Systems and Care Delivery.</p>	Post Date: 9/7/21  Letter of Intent Due: 10/1/21  Proposal by Invitation, Due: 1/10/22	Up to \$32 million for up to 5 years, dependent upon proposal and award mechanism	<a href="https://www.pcori.org/funding-opportunities/announcement/broad-pcori-funding-announcements-cycle-3-2021">https://www.pcori.org/funding-opportunities/announcement/broad-pcori-funding-announcements-cycle-3-2021</a>
82.	Pre-Announcement: Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 3 2021 (PCORI)	N/A	<p>PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. The programmatic priority for artificial intelligence and machine learning replaced the priority for "Methods to Improve the Use of Natural Language Processing (NLP)" as of Cycle 3 2020. This change signals PCORI's broader interest in funding methodological research that seeks to improve how massive amounts of data from a variety of sources can be: (1) appropriately analyzed and integrated into clinical care and health care delivery systems, and (2) facilitate population health models and social determinants of health analyses. Proposals should address mechanisms seeking to improve equitable, inclusive data collection and aggregation. NLP-related proposals will still be considered.</p>	Post Date: 9/7/21  Letter of Intent Due: 10/1/21  Proposal by Invitation, Due: 1/10/22	Up to \$12 million, for up to 3 years	<a href="https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-3-2021">https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-3-2021</a>

<b>RECONSTRUCTIVE TRANSPLANT (2)</b>						
83.	DoD Reconstructive Transplant, Investigator Initiated Research Award and Advanced Technology Development Award (CDMRP/USAMRAA)	W81XW H-21-RTRP-IIRA ; ATDA	The FY21 RTRP Investigator-Initiated Research Award is intended to support studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. Investigator-Initiated Research Award applications may focus on any phase of research from basic through translational, including preclinical studies in animal models, human subjects, human anatomical substances, as well as correlative studies associated with an existing clinical trial. The FY21 RTRP Advanced Technology Development Award is intended to support research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation. Proposed research and products to be developed may be materiel products such as drugs, biologic agents, or devices, or knowledge-based products such as technical reports and clinical practice guidelines that inform clinical/operational decisions and promote evidence-based changes in clinical practice and standard of care.	Pre-Application Due: 9/15/21  Proposal by Invitation, Due: 12/8/21	Up to \$1.5 million dependent upon award  Dependent upon award mechanism	<a href="https://cdmrp.army.mil/funding/rtrp">https://cdmrp.army.mil/funding/rtrp</a>  <a href="https://cdmrp.army.mil/funding/pdf/21rtrpreftable.pdf">https://cdmrp.army.mil/funding/pdf/21rtrpreftable.pdf</a>
<b>REHABILITATION (5)</b>						
84.	Pre-Announcement: Rehabilitation Engineering Research Centers (RERC) Program: RERC on Rehabilitation Strategies, Techniques, and Interventions (HHS/ACL)	HHS-2022-ACL-NIDILRR-REGE-0024	The purpose of the RERC program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended, by conducting advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or to remove environmental barriers for people with disabilities. RERCs also demonstrate and evaluate such technologies, facilitate service delivery system changes, stimulate the production and distribution of new technologies and equipment in the private sector, and provide training opportunities. NIDILRR seeks to fund research and development that leads to rehabilitation technologies, practices, and services that improve the health, and the physical, cognitive, sensory, and communication abilities of people with a wide range of disabling conditions. Rehabilitation engineering in this area should result in new or improved products, devices, and technological advances that enhance rehabilitation services in clinical or community settings.	Estimated Post Date: 12/16/21	Up to \$925,000, for up to five years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334811">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334811</a>



85.	Pre-Announcement: Field Initiated Projects Program (Research) (HHS/ACL)	HHS-2022-ACL-NIDILRR-IFRE-0009	<p style="text-align: center;"><b>REHABILITATION</b></p> <p>The purpose of the Field Initiated Projects program is to generate new knowledge through research or to develop methods, procedures, and rehabilitation technologies that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and self-sufficiency of people with disabilities, especially people with the highest support needs. In carrying out a research activity under a Field Initiated Projects research grant, a grantee must identify one or more hypotheses or research questions and, based on the hypotheses or research questions identified, perform an intensive, systematic study directed toward producing (1) new scientific knowledge, or (2) better understanding of the subject, problem studied, or body of knowledge.</p>	Estimated Post Date: 10/7/21	Up to \$200,000 for 3 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334763">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334763</a>
86.	Pre-Announcement: Rehabilitation Research and Training Centers (RRTC): Equity Center in the Community Living and Participation Domain; Employment Domain; and Health and Function Domain (HHS/ACL)	<p>HHS-2022-ACL-NIDILRR-RTEM-0026</p> <p>HHS-2022-ACL-NIDILRR-RTEM-0028</p> <p>HHS-2022-ACL-NIDILRR-RTHF-0029</p>	<p>The purpose of the RRTC program is to achieve the goals of, and improve the effectiveness of, services authorized under the Rehabilitation Act of 1973, as amended, through well-designed research, training, technical assistance, and dissemination activities in important topical areas as specified by NIDILRR. These RRTC grants invite applicants to conduct research toward new knowledge of, and reduction of disparities in health and function outcomes among people with disabilities, particularly those in underserved areas/populations. The RRTC must explore and provide detailed information about employment outcome disparities within the population of people with disabilities, across subpopulations defined by race, ethnicity, LGBTQ+ status, or poverty status. New knowledge generated by this Center must ultimately be used toward development and implementation of evidence-based policies, practices, or interventions for achieving more equitable employment outcomes among the heterogeneous population of people with disabilities. The RRTC must serve as a national resource center in this area, and must serve as a resource for the conduct of culturally competent disability and rehabilitation research in the employment domain.</p>	<p>Estimated Post Date: 2/20/22</p> <p>Estimated Proposal Due Date: 4/11/22</p>	Up to \$933,333, for 5 years	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334802">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334802</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334814">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334814</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334815">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334815</a></p>

<b>SCLERODERMA (2)</b>						
87.	FY21 Scleroderma Research Program (SRP) (DoD/CDMRP)	W81XW H-21-SRP-IDA; TRPA	Applications to the FY21 SRP IDA must address the following areas: biomarker definition that informs therapeutic choices, utilization of systems biology to develop drug testing models, studies of diverse populations outcomes to understand disease burden, role of epigenetics, cell types, and molecules that mediate pathogenesis and development of clinical outcome measures to determine treatment efficacy. Awards under SRP are: 1) Idea Development Award: supports innovative, high-risk/high-reward research that could lead to discoveries and/or major advancements in scleroderma research and/or improvements in patient care and/or quality of life & 2) Translational Research Partnership Award: supports partnerships that accelerate the movement of promising ideas in scleroderma research into clinical applications.	Pre-Application Due: 8/18/21  Proposal Due: 9/1/21	Up to \$750,000, for up to 3 years	<a href="https://cdmrp.army.mil/funding/pa/FY21-SRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-SRP-IDA.pdf</a>  <a href="https://cdmrp.army.mil/funding/pa/FY21-SRP-TRPA.pdf">https://cdmrp.army.mil/funding/pa/FY21-SRP-TRPA.pdf</a>
<b>SMALL BUSINESS DEVELOPMENT (5)</b>						
88.	A Solicitation of the NIH and CDC for Small Business Innovation Research Contract Proposals (NIH)	PHS-2022-1	The NIH and the CDC are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives.	Proposal Due: 10/28/21	Phase I: Up to \$400,000 for 1 year  Phase II: Up to \$2 million for up to 2 years	<a href="https://sam.gov/opp/dec33d2b73f245f18e8d8d9f559b3698/view#general">https://sam.gov/opp/dec33d2b73f245f18e8d8d9f559b3698/view#general</a>  <a href="https://sbir.nih.gov/sites/default/files/Contracts-Solicitation-PHS-2022-1.pdf">https://sbir.nih.gov/sites/default/files/Contracts-Solicitation-PHS-2022-1.pdf</a>
89.	Pre-Announcement: Small Business Innovation Research Program (SBIR) Phase I (HHS/ACL)	HHS-2022-ACL-NIDILRR-BISB-0019	The purpose of the Federal SBIR program is to stimulate technological innovation in the private sector, strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs, and improve the return on investment from Federally-funded research for economic and social benefits to the nation. The specific purpose of NIDILRR's SBIR program is to improve the lives of people with disabilities through R/R&D products generated by small businesses, and to increase the commercial application of NIDILRR-supported research results and development products.	Estimated Post Date: 11/15/21	Up to \$100,000, for 6 months	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334820">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334820</a>

90.	Small Business Technology Transfer (STTR) Program Phase I Third Window Submissions (NSF)	21-562 21-563	<p align="center"><b>SMALL BUSINESS DEVELOPMENT</b></p> <p>The NSF SBIR/STTR Program provides non-dilutive funding for the development of deep technologies, based on discoveries in fundamental science and engineering for profound societal impacts, and welcomes the submission of Project Pitches and full proposals (from companies invited to submit) in many <a href="#">technical areas</a>. NSF SBIR and STTR Program Phase I proposers are REQUIRED to submit a three-page "Project Pitch" that outlines the project objectives, technological innovation and associated technical risks. Details regarding this process as well as how to submit a Project Pitch can be found in section V.A of the full solicitation.</p>	Submission window open until 9/2/21	Up to \$256,000, for up to 12 months	<a href="https://www.nsf.gov/pubs/2021/nsf21562/nsf21562.htm">https://www.nsf.gov/pubs/2021/nsf21562/nsf21562.htm</a>  <a href="https://www.nsf.gov/pubs/2021/nsf21563/nsf21563.htm">https://www.nsf.gov/pubs/2021/nsf21563/nsf21563.htm</a>
91.	FY 2022 SBIR/STTR Phase I Release 1 (DOE)	DE-FOA-0002554	Phase I grants resulting from this competition will be made during FY 2022 to small businesses with maximum award sizes of \$200,000 or \$250,000. Refer to the individual topic for its respective maximum award size (a proposal submitted that exceeds the maximum award size for the respective topic will be declined without review). The period of performance will depend on the scope of the effort but will not exceed 12 months.	Letter of Intent Due: 8/30/21  Proposal Due: 10/21/21	Up to \$250,000, dependent upon proposal	<a href="https://science.osti.gov/sbir/Funding-Opportunities">https://science.osti.gov/sbir/Funding-Opportunities</a>  <a href="https://science.osti.gov/-/media/grants/pdf/foas/2022/DE-FOA-0002554.pdf">https://science.osti.gov/-/media/grants/pdf/foas/2022/DE-FOA-0002554.pdf</a>
			<b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT (7)</b>			
92.	Advancing Informal STEM Learning (AISL) (NSF)	21-599	The AISL program seeks to advance new approaches to and evidence-based understanding of the design and development of STEM learning opportunities for the public in informal environments; provide multiple pathways for broadening access to and engagement in STEM learning experiences; advance innovative research on and assessment of STEM learning in informal environments; and engage the public of all ages in learning STEM in informal environments. The AISL program supports six types of projects: (1) Pilots and Feasibility Studies, (2) Research in Service to Practice, (3) Innovations in Development, (4) Broad Implementation, (5) Literature Reviews, Syntheses, or Meta-Analyses, and (6) Conferences.	Proposal Due: 1/18/22	Up to \$3 million, for up to 5 years  Dependent on award mechanism	<a href="https://www.nsf.gov/pubs/2021/nsf21599/nsf21599.htm#award_info">https://www.nsf.gov/pubs/2021/nsf21599/nsf21599.htm#award_info</a>
93.	Cybersecurity Workforce Development and Training Pilot for Underserved Communities (DHS)	DHS-21-CISA-127-CWDT001	This cooperative agreement seeks to leverage the unrealized cybersecurity talent of underserved communities through established or emerging non-traditional technical training providers that create or enhance existing entry-level training and apprenticeship programs. To optimize and expand existing cybersecurity training and apprenticeship programs, the development and implementation of a comprehensive cybersecurity pathways retention strategy, is needed.	Proposal Due: 8/25/21	Up to \$1 million, for up to 3 years	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=94010">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=94010</a>

<b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b>						
94.	NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed) (NIH)	PAR-21-258	NIAID seeks to further promote diversity in research training and education programs by developing programs that ultimately support the increased participation and retention of undergraduate, graduate, health professional students, postdoctoral fellows, and early career investigators from nationally underrepresented backgrounds as defined in the Notice of NIH's Interest in Diversity, <a href="#">NOT-OD-20-031</a> . By supporting educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce, NIAID strives to increase the pool of current and future research investigators from diverse backgrounds.	Letter of Intent Due: 8/10/21 12/25/21 4/25/22  Applications due: 9/10/21 1/25/22 5/25/22	Up to \$325,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-258.html">https://grants.nih.gov/grants/guide/pa-files/PAR-21-258.html</a>
95.	New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional) (NIH/NHGRI/NIBIB)	RFA-HG-21-041	This FOA solicits R01 grant applications that propose independent research projects within the scientific mission areas of the NHGRI NIBIB, and All of Us Research Program. This program is intended to support Early Stage Investigators and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences workforce. The NIH expects efforts to diversify the workforce to lead to the recruitment of the most talented researchers from all groups; to improve the quality of the educational and training environment; to balance and broaden the perspective in setting research priorities; to improve the ability to recruit subjects from minority and other health disparity populations into clinical research protocols; and to improve the Nation's capacity to address and eliminate health disparities.	Letter of Intent Due: 1/22/22 1/22/23 1/22/24  Proposal Due: 2/22/22 2/22/23 2/22/24	Up to \$500,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-041.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-041.html</a>
96.	Genome Research Experiences to Attract Talented Undergraduates into the Genomics Field to Enhance Diversity (R25 Clinical Trial Not Allowed) (NIH/NHGRI)	RFA-HG-21-033	The over-arching goal of this program is to support educational activities that encourage undergraduates from diverse backgrounds, such as those from groups underrepresented in the biomedical workforce and sexual and gender minorities, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences and Courses for Skills Development.	Letter of Intent Due: 11/1/21 6/1/22 6/1/23  Proposal Due: 12/1/21 7/1/22 7/1/23	Up to \$350,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-033.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-033.html</a>

97.	Creating an Educational Nexus for Training in Experimental Rigor & Materials to Enhance Training in Experimental Rigor (UC2/UE5 Clinical Trial Not Allowed) (NIH/NINDS)	RFA-NS-21-009 (UC2) RFA-NS-21-033 (UE5)	<p align="center"><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>RFA-NS-21-009 supports the establishment of a center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), which will build, evaluate, and disseminate a user-friendly, harmonized, and openly accessible educational resource to promote awareness, understanding, and utilization of the principles of rigorous biomedical research. RFA-NS-21-033 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments.</p>	<p>Letter of Intent Due: 9/21/21</p> <p>Proposal Due: 10/21/21 (both) 10/11/22 10/10/23 (UE5)</p>	<p>Award dependent upon proposal, for up to 5 years (UC2)</p> <p>Up to \$250,000, for up to 3 years (UE5)</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-009.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-033.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-033.html</a></p>
			<b>SUBSTANCE ABUSE (2)</b>			
98.	Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed) (NIH/NIDA)	RFA-DA-22-018; 023	This FOA seeks grant applications from small business concerns to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities. In determining the readiness of the applicants to move past the TV stage and the responsiveness to this solicitation, NIDA will use both: A) robustly demonstrated proof of target validation and B) a clearly defined Target Product Profile (TPP).	Proposal Due: 2/18/22	<p>Phase I: Up to \$320,000, for up to 1 year</p> <p>Phase II: Up to \$2.5 million, for up to 2 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-018.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-023.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-023.html</a></p>

			<b>TRAUMATIC BRAIN INJURY (7)</b>			
99.	Traumatic Brain Injury and Psychological Health Research Program (DoD/CDMRP)	W81XWH-21-S-TBIPH1; TBIPH2  W81XWH-21-TBIPHRP-IDA; IIRA; TRA; CDRA	<p>The FY21 TBIPHR solicits research applications addressing at least one of the Focus Areas described below through six different award mechanisms:</p> <ul style="list-style-type: none"> <li>• Clinical Trial (W81XWH-21-S-TBIPH1)</li> <li>• Focused Program (W81XWH-21-S-TBIPH2)</li> <li>• Idea Development (W81XWH-21-TBIPHRP-IDA)</li> <li>• Investigator-Initiated Research (W81XWH-21-TBIPHRP-IIRA)</li> <li>• Translational Research Awards (W81XWH-21-TBIPHRP-TRA)</li> <li>• Clinical Research Development (W81XWH-21-TBIPHRP-CRDA)</li> </ul> <p>The Focus Areas broadly include the following but not all of which will be applicable to every award mechanism: 1) Knowledge gaps in foundational science, epidemiology, and etiology of TBI and psychological health, 2) Prevention or progression of TBI or psychological health conditions through population, selective, and indicated prevention approaches. Efforts that focus on primary prevention (including protection), screening, diagnosis, and prognosis are within scope, 3) Immediate and long-term treatments and improvements in systems of care, including access to and delivery of health care services. Treatment topics may include novel treatments and interventions, personalized medicine approaches, length and durability of treatment, rehabilitation, relapse, and relapse prevention.</p>	<p>Pre-Application Due: 9/8/21</p> <p>Proposal by Invitation, Due: 9/30/21 (IDA, IIRA, CDRA)</p> <p>Pre-Application Due: 9/15/21</p> <p>Proposal by Invitation, Due: 12/16/21 (TBIPH1, TBIPH2, TRA)</p>	<p>Up to \$8 million, for up to 4 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CTA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CTA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-FPA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-FPA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IDA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IIRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-TRA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-TRA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CRDA.pdf">https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CRDA.pdf</a></p>
100.	Pre-Announcement: Disability and Rehabilitation Research Projects (DRRP) Program: Traumatic Brain Injury Model System Centers (HHS/ACL)	HHS-2022-ACL-NIDILRR-DPTB-0039	<p><b>TRAUMATIC BRAIN INJURY</b></p> <p>The Traumatic Brain Injury Model System Centers provide comprehensive, multidisciplinary services to people with TBI as a prerequisite for conducting research that contributes to the development of and access to evidence-based TBI rehabilitation with the ultimate goal of improving the health and function, community living and participation, and employment outcomes of people with TBI. TBIMS Centers generate new knowledge through site-specific research projects, collaborative projects, and contributions of data to the TBIMS national longitudinal database.</p>	Estimated Post Date: 1/25/22	Up to \$490,000 for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334823">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334823</a>

<b>VACCINES (1)</b>						
101.	Pre-Announcement: US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings (CDC/ERA)	RFA-IP-22-004	Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.	Estimated Post Date: 12/1/21  Estimated Due Date: 2/1/22	Up to \$11.6 million	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334859">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334859</a>
<b>VISION (1)</b>						
102.	Pre-Announcement: Rehabilitation Engineering Research Centers (RERC) Program: RERC on Blindness and Low Vision (HHS/ACL)	HHS-2022-ACL-NIDILRR-REGE-0023	The purpose of the RERC program is to improve the effectiveness of services by conducting advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or to remove environmental barriers for people with disabilities. RERCs also demonstrate and evaluate such technologies, facilitate service delivery system changes, stimulate the production and distribution of new technologies and equipment in the private sector, and provide training opportunities. This opportunity is for an RERC to conduct research and development activities toward technologies that will promote independence and community living among people who are blind or who have low vision.	Estimated Post Date: 2/3/22	Up to \$925,000, for up to 5 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334824">https://www.grants.gov/web/grants/view-opportunity.html?oppId=334824</a>

			<b>OTHER (7)</b>			
103.	2021 Human Exploration Research Opportunities (HERO) (NASA)	NNJ21ZS A001N  NNJ21ZS A001N-FLAGSH IP  NNJ21ZS A001N-OMNIBUS	<p>A NASA Research Announcement (NRA), entitled, “Human Exploration Research Opportunities (HERO)” (NNJ21ZSA001N), has been released. This NRA will solicit applied research in support of NASA’s Human Research Program (HRP). The research will fall into one or more categories corresponding to HRP’s five Elements: Space Radiation, Human Health Countermeasures, Exploration Medical Capability, Human Factors and Behavioral Performance, and Research Operations and Integration. This NRA covers all aspects of research to provide human health and performance countermeasures, knowledge, technologies, and tools to enable safe, reliable, and productive human space exploration.</p> <p><a href="#">2021 HERO Appendix A</a>: Research and Technology Development to Support Crew Health and Performance in Space Exploration Missions</p> <p><a href="#">2021 HERO Appendix B</a>: NASA Human Research Program Omnibus Opportunity</p>	<p>Step-1 Proposals Due: 9/1/21</p> <p>Step-2 Proposals Due: 12/1/21</p>	Dependent upon proposal	<a href="https://nspires.nasa.prs.com/external/solicitations/summary.do?solId={0F432729-9D9C-B999-EDE8-78E76682B51B}&amp;path=&amp;method=init">https://nspires.nasa.prs.com/external/solicitations/summary.do?solId={0F432729-9D9C-B999-EDE8-78E76682B51B}&amp;path=&amp;method=init</a>
104.	Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (NSF)	NSF 20-575	The Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH) plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need to promote research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support innovative activities by existing teams.	<p>Submission Window: 9/1/21-9/18/21</p> <p>9/1/22-9/18/22</p>	<p>Track 1: Up to \$600,000, for up to 3 years</p> <p>Track 2: Up to \$1.2 million, for up to 4 years</p>	<a href="https://www.nsf.gov/pubs/2020/nsf20575/nsf20575.htm">https://www.nsf.gov/pubs/2020/nsf20575/nsf20575.htm</a>
105.	Mathematical Biology (NSF)	PD-18-7334	The Mathematical Biology Program supports research in areas of applied and computational mathematics with relevance to the biological sciences. Successful proposals are mathematically innovative and address challenging problems of interest to members of the biological community. Some projects of interest to the Mathematical Biology Program may include development of mathematical concepts and tools traditionally seen in other disciplinary programs within the Division of Mathematical Sciences, e.g., topology, probability, statistics, computational mathematics, etc.	Submission Window: 8/20/21-9/5/21	Dependent upon proposal	<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5690">https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5690</a>



106.	Focused Research Groups in the Mathematical Sciences (FRGMS) (NSF)	NSF 16-577	<p style="text-align: center;"><b>OTHER</b></p> <p>The purpose of the Focused Research Group activity is to support collaborative groups employing innovative methods to solve specific, major research challenges in the mathematical sciences. A major challenge is an outstanding problem of significant importance that requires the focused and synergistic efforts of a collaborative group to solve, and whose solution will have wide impacts in the mathematical sciences and potentially in other areas. Groups may include, in addition to statisticians and mathematicians, researchers from other science and engineering disciplines appropriate for the proposed research. Risky projects are welcome. Interdisciplinary projects are welcome.</p>	Proposal Due: 9/8/21	Up to \$500,000 per year, for up to three years	<a href="https://www.nsf.gov/pubs/2016/nsf16577/nsf16577.htm">https://www.nsf.gov/pubs/2016/nsf16577/nsf16577.htm</a>
107.	Pre-Announcement: Grants to Support New Investigators in Conducting Research Related to Preventing Interpersonal Violence Impacting Children and Youth (CDC/ERA)	RFA-CE-22-002	<p>The purpose of the NCIPC Mentored Research Scientist Development Award (K01) is to provide support for an intensive, supervised (mentored) career development experience in violence prevention research leading to research independence. NCIPC supports K01 grants to help ensure the availability of an adequate number of trained scientists to address critical public health research questions to prevent violence and injury. Applicants must propose a research project that addresses at least one of the research priorities in the interpersonal violence prevention section of the <u>NCIPC Research Priorities</u> as they relate to violence impacting children or youth (from birth through age 17). These research priorities include: Cross-cutting violence prevention; Child abuse and neglect; Youth violence; Intimate partner violence; Sexual violence.</p>	<p>Estimated Post Date: 9/30/21</p> <p>Estimated Proposal Due Date: 12/31/21</p>	Up to \$150,000	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=335217">https://www.grants.gov/web/grants/view-opportunity.html?oppId=335217</a>